Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Locatelli. João Carlos JC; Costa. Juliene Gonçalves JG; Haynes. Andrew A; Naylor. Louise H LH; Fegan. P Gerry PG; Yeap. Bu B BB; Green. Daniel J DJ
Key Findings
- Incretinâbased drugs (GLPâ1, GIP, glucagon agonists) produce large fat loss but also rapid leanâmass loss comparable to years of aging.
- Supervised resistance exercise for >10 weeks can increase lean mass by ~3âŻkg and strength by ~25% in both men and women.
- Combining aerobic exercise with liraglutide after a lowâcalorie diet improves weightâloss maintenance versus either strategy alone.
Practical Outcomes
- If youâre using retatrutide or similar peptides for weight loss, schedule regular resistanceâtraining sessions (e.g., 3â4 times per week, focusing on progressive overload) for at least 10 weeks to protect muscle. Pair this with adequate protein intake (â1.6â2.2âŻg/kg body weight) and consider adding aerobic work for overall health and better weightâmaintenance after stopping the drug.
Summary
New weightâloss peptides like retatrutide can help you drop 15â24% of body weight, but they also cause a noticeable loss of muscle (about 10% or 6âŻkg). Adding a structured resistanceâtraining program (at least 10 weeks long) can add back roughly 3âŻkg of lean mass and boost strength by ~25%, helping you keep the muscle you lose while still burning fat.
Abstract
This narrative review highlights the degree to which new antiobesity medications based on gut-derived nutrient-stimulated hormones (incretins) cause loss of lean mass, and the importance of resistance exercise to preserve muscle. Glucagon-like peptide 1 receptor agonists (GLP-1RA) induce substantial weight loss in randomized trials, effects that may be enhanced in combination with glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. Liraglutide and semaglutide (GLP-1RA), tirzepatide (GLP-1 and GIP receptor dual agonist), and retatrutide (GLP-1, GIP, and glucagon receptor triple agonist) are peptides with incretin agonist activity that induce ∼15-24% weight loss in adults with overweight and obesity, alongside beneficial impacts on blood pressure, cholesterol, blood glucose, and insulin. However, these agents also cause rapid and significant loss of lean mass (∼10% or ∼6 kg), comparable to a decade or more of aging. Maintaining muscle mass and function as humans age is crucial to avoiding sarcopenia and frailty, which are strongly linked to morbidity and mortality. Studies indicate that supervised resistance exercise training interventions with a duration >10 weeks can elicit large increases in lean mass (∼3 kg) and strength (∼25%) in men and women. After a low-calorie diet, combining aerobic exercise with liraglutide improved weight loss maintenance compared with either alone. Retaining lean mass during incretin therapy could blunt body weight (and fat) regain on cessation of weight loss pharmacotherapy. We propose that tailored resistance exercise training be recommended as an adjunct to incretin therapy to optimize changes in body composition by preserving lean mass while achieving fat loss.
Study Information
pubmed
2024
2024-10-01T00:00:00.000Z
10.2337/dci23-0100
73